Oleandrin

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameOleandrin
Drug Alias NameOleandrin - Phoenix BiotechnologyPBI 05204 - Phoenix BiotechnologyPBI-05204
ClassificationNatural product/ExtractSmall molecules
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitors70-kDa ribosomal protein S6 kinases inhibitorsSodium/potassium-transporting ATPase inhibitors +[8] 
TargetsNuclear factor NF-kappa-B complex70-kDa ribosomal protein S6 kinasesSodium/potassium-transporting ATPase +[7] 
Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUS Army Medical Research Institute of Infectious DiseasesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPhoenix Biotechnology IncThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsSolid tumoursPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG